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Cold-reactive autoantibodies can mask the presence of underlying 
clinically significant alloantibodies in a patient’s plasma or 
serum. These autoantibodies are problematic when performing 
laboratory procedures such as ABO typing, red blood cell 
(RBC) crossmatching, antibody detection testing, and antibody 
identification. To avert the masking of clinically significant 
alloantibodies in a patient’s plasma or serum, adsorption studies 
can be performed at 4°C using autologous RBCs if the patient 
has not been recently transfused. Immunohematology 
2018;34:158–160.
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Principle
Adsorption studies at 4°C using autologous red blood cells 
(RBCs) (cold autoadsorption) is a process for removing cold-
reactive autoantibodies from a patient’s serum or plasma.1 
This process can only be performed on patients who have not 
been recently transfused (within 3 months) with donor RBCs. 
During cold autoadsorption, the patient’s RBCs are mixed 
with the patient’s plasma or serum and incubated at 4°C. 
During this incubation, the autoantibodies adsorb (attach) to 
the patient’s RBCs, removing them or reducing their strength. 
The adsorbed plasma or serum can then be tested against a 
panel of RBCs to identify underlying clinically significant 
alloantibodies.1,2
Indications
Cold autoantibodies that are present in a patient’s serum 
or plasma can be removed by adsorption using autologous 
RBCs. The adsorbed plasma is used to perform pretransfusion 
testing, which includes RBC compatibility testing, ABO 
typing, antibody detection, and antibody identification. Cold 
autoantibodies are present in the sera of most adults, with 
the most common specificities being anti-I, -H, and -IH.3 
In most cases, cold autoantibodies are IgM and are of no 
clinical significance, with the exception of those related to 
cold agglutinin syndrome, which routinely express high titers 
(>1000) and high thermal amplitude.4
Serum or plasma that contains cold-reactive autoanti-
bodies most commonly reacts with reagent screening RBCs 
and panel RBCs and with untreated autologous RBCs at the 
immediate spin (IS) phase, but reactivity becomes weaker or 
disappears when the serum/cell mixture is incubated at 37°C.3 
Although most cold-reactive autoantibodies react at IS and at 
lower temperatures during serologic testing, it is important to 




• Patient’s plasma/serum containing 
cold autoantibody
• Normal saline or PBS
• Proteolytic enzyme (optional)
• Reagent screening RBCs
• Anti-IgG 
• IgG-coated RBCs
• Potentiators such as LISS
• 1 mL graduated, 
disposable pipettes
• Crushed ice to make a 4°C 
environment or refrigerator




RBC = red blood cell; PBS = phosphate-buffered saline; LISS = 
low-ionic-strength saline.
Procedural Steps
• Ensure that the patient has not been recently transfused (within the 
last 3 months).
• Wash the patient’s RBCs at least three times with warm saline.
• Centrifuge the RBCs for at least 5 minutes and remove the 
supernatant saline.
• If treatment with proteolytic enzymes is desired, follow 
manufacturer’s directions and treat the RBCs.
• Wash the RBCs four times after enzyme treatment.
• Centrifuge for at least 5 minutes after the last wash and remove 
supernatant saline. If available, use filter paper to carefully adsorb 
out any residual saline.
• Add 1 volume of plasma/serum to 1–2 volumes of washed, packed 
autologous RBCs.
• Stopper, gently mix well, and incubate for 30–60 minutes at 4°C.
• Centrifuge for 5 minutes and remove the plasma/serum. Test the 
adsorbed plasma/serum with reagent screening RBCs to see if all 
or most of the cold autoantibody reactivity has been removed.
• Repeat the procedure with fresh adsorbing RBCs if further 
adsorption is needed.
RBCs = red blood cells.
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detected at the antihuman globulin (AHG) phase of testing.5 
These autoantibodies may be mistaken for the presence of 
weakly reactive alloantibodies.3 To mitigate this situation, the 
use of monospecific anti-IgG at the AHG phase of testing is 
necessary, although reactivity may persist with monoclonal 
anti-IgG.
Identifying the specificity of antigen that a cold-reactive 
autoantibody is directed against is not of routine laboratory 
interest, although further testing to determine the identity 
of the autoantibody can be performed by various methods. 
For example, testing cord RBCs alongside reagent screening 
RBCs can confirm the presence of anti-I, since cord RBCs 
have less expression of the I antigen and would react 
weakly or negatively against anti-I. Anti-IH, which is more 
commonly found in individuals with A1B, A1, and B blood 
groups, reacts more strongly with RBCs that have a strong 
expression of the H antigen. Identification of the antigen to 
which the autoantibody is reacting will assist the technician in 
understanding properties that may be influenced by modifiers 
such as enzyme treatment.
Procedure
Ensure that the patient has not been transfused within the 
last 3 months and there is a sufficient quantity of autologous 
RBCs to perform the adsorption.1 Concentrate the autologous 
RBCs by centrifuging for 5 minutes. The use of large-bore 
tubes (16 × 100 mm) for adsorption is recommended because 
adsorption is more effective if the area of contact between 
plasma or serum and the adsorbing RBCs is large.6 Obtain 
an aliquot of the patient’s packed RBCs and wash at least four 
times with large volumes of warm saline until supernatant is 
clear. After the last wash, centrifuge the RBCs for at least 5 
minutes and remove the supernatant saline using disposable 
pipettes. Treat the washed, packed autologous RBCs with a 
proteolytic enzyme such as papain to enhance the adsorption 
process. Alternatively, ZZAP, a combination of proteolytic 
enzyme and dithiothreitol, can be used to treat the patient’s 
RBCs before adsorption.2 Follow the manufacturer’s directions 
on performing RBC treatments with proteolytic enzymes 
if using commercially made enzymes. Wash the RBCs at 
least four times after enzyme treatment. After the last wash, 
centrifuge the RBCs for at least 5 minutes and remove as much 
residual saline as possible using disposable pipettes to prevent 
dilution of the RBCs. Filter paper may be used to carefully 
adsorb residual saline. Aliquot the RBCs into additional tubes 
if multiple adsorptions are desired and the volume is sufficient.
Combine 1–2 volumes of autologous RBCs to 1 volume 
of patient’s plasma or serum in an appropriately labeled tube 
and mix gently.2 Incubate the tube at 4°C for 30 minutes. Mix 
the autologous RBCs/serum or plasma mixture periodically 
throughout the incubation period to enhance adsorption. 
Observe for agglutination/clumping on the sides of the tube. 
If visible clumping is observed after at least 15 minutes of 
incubation, proceed to the next step before completion of the 
30-minute incubation time if desired. After the incubation 
period has elapsed, centrifuge the RBCs/serum or plasma 
mixture for at least 5 minutes to pack the RBCs. If more 
adsorptions are desired, transfer the adsorbed plasma/serum 
to another tube of enzyme-treated, or ZZAP-treated, RBCs 
and repeat the incubation step.
If additional adsorptions are desired and autologous RBCs 
are limited, adsorptions may be repeated on the already-used 
adsorbing RBCs by re-treating the RBCs with proteolytic 
enzyme or ZZAP.1 It is important to note that overtreatment 
with ZZAP can cause RBCs to hemolyze. If no more adsorptions 
are desired, transfer the adsorbed plasma/serum into a clean, 
properly labeled test tube and discard the adsorbing RBCs. 
Test an aliquot of the adsorbed plasma with reagent screening 
RBCs and an untreated 3–5 percent suspension of the 
patient’s cells. Potentiators may be used to enhance reactivity 
of weakly reacting alloantibodies or alloantibodies that may 
be showing dosage. Using potentiators such as albumin or 
polyethylene glycol in a mixture of reagent RBCs and adsorbed 
plasma/serum may enhance any cold autoantibodies that are 
left behind during the adsorption process.1,3 It is important 
to note that testing adsorbed plasma/serum with screening 
RBCs is not a standard practice to determine the endpoint 
of adsorption but can be used as an optional method. If the 
adsorbed plasma/serum does not react with the screening 
RBCs, then the autoantibody has been adsorbed and, most 
likely, the plasma/serum does not contain alloantibodies.
It is suggested to test the autoadsorbed plasma/serum 
in parallel with unadsorbed plasma/serum. If the adsorbed 
plasma/serum reacts with the screening RBCs and adsorption 
is determined to be complete, perform antibody identification 
using a panel of reagent RBCs.
Reactivity with the reagent RBCs may be variable in 
strength and may be observed with one reagent RBC and 
not the other. It is important to note that clinically significant 
antibodies, especially those weak or variable in test strength, 
such as anti-Vel, may be missed. Anti-Vel may present as 
a benign, cold-reactive IgM antibody, but it is capable of 
fixing complement at body temperature, which can cause a 
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severe hemolytic transfusion reaction. To assist in evaluating 
the clinical significance of cold-reacting antibodies, other 
procedures such as antibody titration and thermal amplitude 
studies may be necessary.
The use of adsorption studies at 4°C using autologous 
RBCs can be beneficial to avert the issues that cold-reactive 
autoantibodies pose for serologic testing. The inability to find 
compatible RBCs to transfuse a patient because of the presence 
of cold autoantibody may cause a delay in transfusion and 
unwanted patient safety issues. Adsorption studies to remove 
such autoantibodies is pertinent to ensure that properly 
crossmatched blood is available for transfusion.
Limitations
Adsorption is a time-consuming process that may take 
several hours to complete, especially if multiple adsorptions are 
necessary to remove enough autoantibody from the patient’s 
plasma/serum to resolve serologic problems.
Performing adsorptions presents the risk of diluting 
weakly reactive alloantibodies with residual saline if the saline 
is not carefully removed after the last wash of the autologous 
RBCs before adding patient’s plasma or serum. The use of a 
potentiator such as low-ionic-strength saline solution can help 
to enhance the strength of weakly reactive antibodies that may 
have been diluted.
Another limitation with autologous adsorption is that if 
the patient has a very low hematocrit and not enough packed 
RBCs available for testing, adsorption with autologous RBCs 
may not be possible.
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